Brokerages expect Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) to report earnings of ($0.12) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aptose Biosciences’ earnings. Aptose Biosciences posted earnings of ($0.24) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The firm is scheduled to report its next earnings results on Monday, November 13th.

According to Zacks, analysts expect that Aptose Biosciences will report full-year earnings of ($0.57) per share for the current year. For the next fiscal year, analysts forecast that the company will post earnings of ($0.52) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07.

APTO has been the subject of several analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $7.00 price target on shares of Aptose Biosciences in a report on Friday, May 12th. Rodman & Renshaw initiated coverage on shares of Aptose Biosciences in a report on Thursday, June 8th. They issued a “neutral” rating for the company. ValuEngine raised shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. HC Wainwright initiated coverage on shares of Aptose Biosciences in a report on Thursday, June 8th. They issued a “hold” rating for the company. Finally, Zacks Investment Research raised shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Aptose Biosciences presently has a consensus rating of “Buy” and a consensus price target of $6.50.

Shares of Aptose Biosciences (APTO) traded up 3.45% on Friday, reaching $1.50. 282,143 shares of the company’s stock traded hands. Aptose Biosciences has a one year low of $0.78 and a one year high of $3.20. The company’s 50-day moving average price is $1.48 and its 200 day moving average price is $1.22. The firm’s market cap is $36.04 million.

WARNING: “Zacks: Brokerages Anticipate Aptose Biosciences, Inc. (APTO) Will Announce Earnings of -$0.12 Per Share” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with's FREE daily email newsletter.